Zenith Drugs share news and announcements
NSE: ZENITHDRUGPharmaceuticals & Biotechnology
Share price at the NSE close on 23 Oct 2026. Previous close ₹38.20.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price.
- ₹68 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 15 Jun 2026
- 17.2
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 15 Jun 2026
- 0.9
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 15 Jun 2026
- 5.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 15 Jun 2026
- 0.75
- Volume, NSEVolume. Shares traded on the last trading day.
- 3,200
Last results date
The last board meeting held for results; the company has not yet given notice of the next.Zenith Drugs half-yearly results
The board met on 29 May 2026 to consider financial results and other business matters
Notice filed 25 May 2026
Zenith Drugs annual reports, presentations and earnings calls
The company's own documents, latest first.Zenith Drugs financials, year by year
Annual reports3
Zenith Drugs share news and announcements
103 announcements, routine notices left out, newest first. Page 1 of 3.
Oct 2026
13 Oct · Board meeting
10 Oct · General Updates
Sep 2026
5 Sep · Board meeting
Aug 2026
26 Aug · Board meeting
Jul 2026
Jun 2026
26 Jun · Board meeting
15 Jun · Board meeting
8 Jun · General Updates
May 2026
25 May · General Updates
Apr 2026
Feb 2026
6 Feb · General Updates
Jan 2026
30 Jan · General Updates
Dec 2025
26 Dec · General Updates
18 Dec · General Updates
13 Dec · General Updates
Nov 2025
19 Nov · General Updates
14 Nov · Board meeting
11 Nov · General Updates
8 Nov · Business
4 Nov · General Updates
Oct 2025
Sep 2025
4 Sep · Corporate action
4 Sep · Board meeting
Aug 2025
Jul 2025
Jun 2025
How the price met the news
The first session after each announcement, beside the market.
That dayThe first session's move. The first session's close after the announcement against the close before it, as a per cent change, on prices adjusted for splits and bonuses.Against the Nifty 500Against the Nifty 500. The share's move less the Nifty 500's move the same session, in percentage points (pts).Market median on that newsThe market's median move on that news. The middle first-session move of every listed company that filed the same kind of announcement, half moving more and half less.Five sessionsFive sessions' move. The close five sessions after the announcement against the close before it, as a per cent change.Five sessions against the Nifty 500Five sessions against the Nifty 500. The share's five-session move less the Nifty 500's move over the same five sessions, in percentage points (pts).Volume, times usualVolume, times usual. The session's shares traded divided by the average of the twenty sessions before it.
- 1 Jun 2026Resultsdown 9.07%−8.1 pts vs Nifty 500market median −0.7% · five sessions −15.3% (−14.5 pts vs Nifty 500) · volume 1.6× usual · The announcement (opens in a new tab)
- 17 Nov 2025Resultsdown 8.85%−9.3 pts vs Nifty 500market median −0.7% · five sessions −3.9% (−3.7 pts vs Nifty 500) · volume 3.7× usual · The announcement (opens in a new tab)
- 10 Nov 2025Order receiveddown 2.85%−3.2 pts vs Nifty 500market median +1.1% · five sessions −6.1% (−7.4 pts vs Nifty 500) · volume 1.9× usual · The announcement (opens in a new tab)
- 1 Sep 2025Board or managers changedup 1.17%+0.1 pts vs Nifty 500market median 0.0% · five sessions +2.0% (+0.4 pts vs Nifty 500) · volume 0.8× usual · The announcement (opens in a new tab)
- 30 May 2025Resultsdown 5.00%−4.7 pts vs Nifty 500market median −0.7% · five sessions −14.9% (−15.3 pts vs Nifty 500) · volume 0.7× usual · The announcement (opens in a new tab)
- 2 Sep 2024Board or managers changeddown 0.09%−0.2 pts vs Nifty 500market median 0.0% · five sessions −1.3% (−0.3 pts vs Nifty 500) · volume 0.7× usual · The announcement (opens in a new tab)
- 30 May 2024Dividenddown 4.06%−3.0 pts vs Nifty 500market median 0.0% · five sessions −6.5% (−5.5 pts vs Nifty 500) · volume 1.1× usual · The announcement (opens in a new tab)
Zenith Drugs results filing dates and deadlines
Listed companies must file half-yearly results within 45 days, and the year's within 60.
Days to fileDays to file. The days from the period's end to the day the results reached the exchange.DeadlineDeadline, days. The days the rules allow from the period's end: 45 for a quarter or half year, and 60 for the year and the March quarter filed with it. A company that listed after the period ended has until 21 days after its listing where that is later.
Figures filed again
Lines the company later filed with a different value, rupee lines in ₹ crore and per-share lines in rupees.
| Line | Period | Accounts | First filed | Filed again | Change. The value filed again less the value first filed, as a per cent of the first. | First filed on | Filed again on |
|---|---|---|---|---|---|---|---|
| Net worth | At Mar 2026 | Standalone | 74.93 | 73.32 | −2.1% | 29 May 2026 (opens in a new tab) | 15 Jun 2026 (opens in a new tab) |
| Reserves | At Mar 2026 | Standalone | 57.78 | 56.17 | −2.8% | 29 May 2026 (opens in a new tab) | 15 Jun 2026 (opens in a new tab) |
| Other liabilities due within a year | At Mar 2026 | Standalone | 1.90 | 1.90 | 0.0% | 29 May 2026 (opens in a new tab) | 15 Jun 2026 (opens in a new tab) |
| Shareholders' funds | At Mar 2026 | Standalone | 74.93 | 73.32 | −2.1% | 29 May 2026 (opens in a new tab) | 15 Jun 2026 (opens in a new tab) |
| Liabilities due within a year | At Mar 2026 | Standalone | 92.48 | 94.08 | +1.7% | 29 May 2026 (opens in a new tab) | 15 Jun 2026 (opens in a new tab) |
| Net worth belonging to the company's shareholders | At Mar 2026 | Standalone | 74.93 | 73.32 | −2.1% | 29 May 2026 (opens in a new tab) | 15 Jun 2026 (opens in a new tab) |